Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05385965 | Meaning-Centered Pain Coping Skills Training for Cancer Pain(MCPC) | completed | N/A | 211 | Duke UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05076396 | PM14 Administered Intravenously to Patients With Advanced Solid Tumors | completed | Phase 1 | 126 | PharmaMarINDUSTRY | 3 | May 11, 2026 | clinicaltrials |
| NCT05387928 |
| A Study of KL340399 in Patients With Advanced Solid Tumors |
| completed |
| Phase 1 |
| 21 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY |
| 1 |
| May 8, 2026 |
| clinicaltrials |
| NCT05549804 | A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors | completed | Phase 1 | 6 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT01705548 | Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis | completed | N/A | 24 | Emory UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04745910 | Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome | completed | Phase 4 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT04457778 | First in Human Study of M6223 | completed | Phase 1 | 58 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT05824663 | A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 17 | Harbour BioMed US, Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT05865990 | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease(TUXEDO-3) | completed | Phase 2 | 63 | MedSIROTHER | 2 | May 4, 2026 | clinicaltrials |
| NCT04118114 | Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors | completed | Phase 2 | 14 | National Cancer Centre, SingaporeOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01625234 | Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 131 | Xcovery Holdings, Inc.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT03218826 | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07554196 | A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors | completed | Phase 1 | 12 | Huahui HealthINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT01787500 | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | completed | Phase 1 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02661542 | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 106 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06308263 | Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) | completed | Phase 1 | 12 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03317743 | Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors | completed | Phase 1 | 32 | Idience Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | completed | Phase 1 | 100 | Compass TherapeuticsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04174716 | Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)(VASTUS) | completed | Phase 1 / Phase 2 | 108 | Idience Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04886271 | Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors | completed | Phase 2 | 20 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT06305884 | Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study | completed | N/A | 76 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04420884 | A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors(iintune-1) | completed | Phase 1 / Phase 2 | 248 | TakedaINDUSTRY | 11 | Apr 8, 2026 | clinicaltrials |
| NCT04983901 | PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT04911907 | Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors | completed | Phase 2 | 126 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04050709 | QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | completed | Phase 1 | 16 | ImmunityBio, Inc.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05148325 | Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors | completed | Phase 1 | 28 | Bio-Thera SolutionsINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02133625 | A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors | completed | Phase 1 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05727839 | Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | completed | Phase 1 | 19 | Immorna Biotherapeutics, Inc.INDUSTRY | 2 | Mar 24, 2026 | clinicaltrials |
| NCT05988892 | A Study of Physical Activity in Cancer Survivors | completed | N/A | 100 | Mayo ClinicOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT04143711 | Study of DF1001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 270 | Dragonfly TherapeuticsINDUSTRY | 6 | Mar 18, 2026 | clinicaltrials |
| NCT04158336 | A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors | completed | Phase 1 | 274 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04423029 | A Study of DF6002 Alone and in Combination With Nivolumab | completed | Phase 1 | 170 | Dragonfly TherapeuticsINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT06108479 | Study of DF6215 in Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Dragonfly TherapeuticsINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT06056024 | A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus | completed | Phase 1 | 47 | Boehringer IngelheimINDUSTRY | 4 | Mar 17, 2026 | clinicaltrials |
| NCT01248429 | Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases(TKI-CPK) | completed | — | 154 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT01415258 | Screening for Vulnerability in the Elderly Supported at the Oscar Lambret Centre(VULNERABILITE) | completed | — | 209 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03725436 | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04261413 | Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 16 | RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.INDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05735366 | A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Chugai PharmaceuticalINDUSTRY | 2 | Mar 10, 2026 | clinicaltrials |
| NCT04695327 | TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy(TUNIMO) | completed | Phase 1 | 32 | TILT Biotherapeutics Ltd.INDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04705818 | Combining Epigenetic And Immune Therapy to Beat Cancer.(CAIRE) | completed | Phase 2 | 164 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04912687 | Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients(CIRCULAR) | completed | N/A | 581 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06340815 | Varian ProBeam Proton Therapy System Clinical Trial (Shandong) | completed | N/A | 47 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT02617277 | Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | completed | Phase 1 | 56 | AstraZenecaINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06881108 | Addressing Financial Hardship in Adolescent and Young Adult Cancer Survivors(FinFit Aim 1) | completed | — | 16 | Wake Forest University Health SciencesOTHER | 1 | Mar 3, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 12, 2026source: clinicaltrials